Foghorn Therapeutics Inc. (FHTX)
Healthcare
- Fundamental
- 2
- Sentiment
- 2
- Technical
- 1
Do Nothing: hard-blocked by gate overrides — fundamentalScore 2 and qualitativeScore 2 are both below the required floor of 3, and avgDollarVolume20 $3.86M is below the $5M liquidity floor; the entry scan is also negative (countertrend pullback limit; no breakout stop clears the 1.0×ATR minimum-risk floor at 19.8% ATR).
Company overview
Foghorn Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing medicines targeting the chromatin regulatory system. Utilizing its proprietary Gene Traffic Control platform, the company aims to address genetically determined vulnerabilities. Its pipeline includes small-molecule agents like FHD-286 and FHD-609, targeting various cancers.
Fundamental
weakFoghorn's fundamentals are speculative with a strong cash position but no revenue, and the company is undergoing restructuring.
Foghorn is a pre-revenue biotech in restructuring: FHD-909 will not advance, the Lilly collaboration is winding down, and about 40% of staff are being cut — offset by a strong net-cash balance sheet ($167.6M of cash and securities against a market capitalization below cash), no debt, and a guided runway into the second half of 2029. Fundamentals are weak and highly speculative; near-term solvency is not in question.
Sentiment
weakSentiment is sharply negative following strategic setbacks and workforce reductions.
Dominant catalyst is the announced 2026-10-01 halt of FHD-909 and the selective SMARCA2 degrader with the Lilly collaboration wind-down, ~40% workforce reduction and a refocus on wholly owned programs (bearish; partially priced), reinforced by same-week analyst downgrades (TD Cowen, Guggenheim) and target cuts. The sentiment delta is determinately negative (baseline ≈ +0.02 → scoring ≈ −0.63; item-level read) and the Red-Flag Screen fired the moderate 'sharply deteriorating sentiment with no offsetting bullish catalyst' flag — moderate red-flag cap applied; the setup remains weak, with no actionable long-side spark over the next 1–30 days.
Technical
very weakThe stock is in a strong downtrend, trading below key averages with no bullish confirmation.
Broken-structure read. After the late-September/October catalyst collapse (FHD-909 halt, Lilly collaboration wind-down, 40% workforce reduction), price 1.97 trades below every key average (SMA20 3.67, SMA50 4.99, SMA200 5.02, EMA9 2.82, EMA21 3.63), with MACD negative and widening (line -0.79, histogram -0.17) and ADX 50.5 confirming a powerful downtrend; the lone constructive element is an extreme oversold oscillator set (RSI 12.3, Williams -92.9) that has produced no bullish reclaim. No admissible entry exists: a pullback/oversold limit is countertrend (price < SMA50 with MACD < 0; also below a declining SMA200 without a reclaim), and a breakout stop's structural risk (~0.95×ATR) sits under the 1.0×ATR floor for this 19.8%-ATR name. The action is additionally hard-blocked upstream: fundamentalScore 2 and qualitativeScore 2 (both below the required floor of 3) and avgDollarVolume20 $3.86M below the $5M liquidity floor. TechnicalScore 1 = bearish/broken structure.
You’re looking at 2026-10-06 — more than 2 trading days ago.
Subscribers saw this then, and see today’s score, verdict and trade plan now.
More Healthcare
Not financial advice. For informational and educational purposes only.

